Cargando…

Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis

BACKGROUND: Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish betwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Bella, Chiara, Spinicci, Michele, Grassi, Alessia, Bartalesi, Filippo, Benagiano, Marisa, Truthmann, Katja, Tapinassi, Simona, Troilo, Arianna, D’Elios, Sofia, Alnwaisri, Heba, Shuralev, Eduard, Singh, Mahavir, Bartoloni, Alessandro, D’Elios, Mario Milco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983515/
https://www.ncbi.nlm.nih.gov/pubmed/29856871
http://dx.doi.org/10.1371/journal.pone.0197825
_version_ 1783328437778251776
author Della Bella, Chiara
Spinicci, Michele
Grassi, Alessia
Bartalesi, Filippo
Benagiano, Marisa
Truthmann, Katja
Tapinassi, Simona
Troilo, Arianna
D’Elios, Sofia
Alnwaisri, Heba
Shuralev, Eduard
Singh, Mahavir
Bartoloni, Alessandro
D’Elios, Mario Milco
author_facet Della Bella, Chiara
Spinicci, Michele
Grassi, Alessia
Bartalesi, Filippo
Benagiano, Marisa
Truthmann, Katja
Tapinassi, Simona
Troilo, Arianna
D’Elios, Sofia
Alnwaisri, Heba
Shuralev, Eduard
Singh, Mahavir
Bartoloni, Alessandro
D’Elios, Mario Milco
author_sort Della Bella, Chiara
collection PubMed
description BACKGROUND: Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish between latent infection and active tuberculosis is one of the major limits of currently available diagnostic tools. METHODS: A total of 215 patients were included in the study as active TB cases (n = 73), LTBI subjects (n = 88) and healthy persons (n = 54). Peripheral blood mononuclear cells (PBMCs) were isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot assay was performed to test their proliferative response to M. tuberculosis antigens ESAT-6, CFP-10 and Ala-DH. Statistical analysis was performed to define the sensitivity and the specificity of the LIOSpot® TB kit for each antigen used and to set the best cut off value that enables discrimination between subjects with active TB or latent TB infection. RESULTS: Comparing the LIOSpot® TB results for each tested antigen between uninfected and infected subjects and between people with latent infection and active TB disease, the differences were significant for each antigen (p< 0.0001) but the ROC analysis demonstrated a high accuracy for the Ala-DH test only, with a cut off value of 12.5 SFC per million PBMCs and the Ala-DH ROC curve conferred a 96% sensitivity and 100% specificity to the test. For the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a sensitivity of 86% and specificity of 36% was obtained. Finally, the best cut off value for CFP-10 was 231.25 SFC per million PBMCs, with a sensitivity of 80% and a specificity of 54%. Thus, as for IGRA assays such as Quantiferon and T-Spot TB tests, ESAT-6 and CFP-10 are unable to distinguish LTBI from active TB when IL-2 is measured. On the contrary, the IL-2 production induced by Ala-DH, measured by LIOSpot® TB kit, shows high sensitivity and specificity for active TB disease. CONCLUSIONS: This study demonstrates that the LIOSpot® TB test is a highly useful diagnostic tool to discriminate between latent TB infection and active tuberculosis in adults patients.
format Online
Article
Text
id pubmed-5983515
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59835152018-06-16 Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis Della Bella, Chiara Spinicci, Michele Grassi, Alessia Bartalesi, Filippo Benagiano, Marisa Truthmann, Katja Tapinassi, Simona Troilo, Arianna D’Elios, Sofia Alnwaisri, Heba Shuralev, Eduard Singh, Mahavir Bartoloni, Alessandro D’Elios, Mario Milco PLoS One Research Article BACKGROUND: Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish between latent infection and active tuberculosis is one of the major limits of currently available diagnostic tools. METHODS: A total of 215 patients were included in the study as active TB cases (n = 73), LTBI subjects (n = 88) and healthy persons (n = 54). Peripheral blood mononuclear cells (PBMCs) were isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot assay was performed to test their proliferative response to M. tuberculosis antigens ESAT-6, CFP-10 and Ala-DH. Statistical analysis was performed to define the sensitivity and the specificity of the LIOSpot® TB kit for each antigen used and to set the best cut off value that enables discrimination between subjects with active TB or latent TB infection. RESULTS: Comparing the LIOSpot® TB results for each tested antigen between uninfected and infected subjects and between people with latent infection and active TB disease, the differences were significant for each antigen (p< 0.0001) but the ROC analysis demonstrated a high accuracy for the Ala-DH test only, with a cut off value of 12.5 SFC per million PBMCs and the Ala-DH ROC curve conferred a 96% sensitivity and 100% specificity to the test. For the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a sensitivity of 86% and specificity of 36% was obtained. Finally, the best cut off value for CFP-10 was 231.25 SFC per million PBMCs, with a sensitivity of 80% and a specificity of 54%. Thus, as for IGRA assays such as Quantiferon and T-Spot TB tests, ESAT-6 and CFP-10 are unable to distinguish LTBI from active TB when IL-2 is measured. On the contrary, the IL-2 production induced by Ala-DH, measured by LIOSpot® TB kit, shows high sensitivity and specificity for active TB disease. CONCLUSIONS: This study demonstrates that the LIOSpot® TB test is a highly useful diagnostic tool to discriminate between latent TB infection and active tuberculosis in adults patients. Public Library of Science 2018-06-01 /pmc/articles/PMC5983515/ /pubmed/29856871 http://dx.doi.org/10.1371/journal.pone.0197825 Text en © 2018 Della Bella et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Della Bella, Chiara
Spinicci, Michele
Grassi, Alessia
Bartalesi, Filippo
Benagiano, Marisa
Truthmann, Katja
Tapinassi, Simona
Troilo, Arianna
D’Elios, Sofia
Alnwaisri, Heba
Shuralev, Eduard
Singh, Mahavir
Bartoloni, Alessandro
D’Elios, Mario Milco
Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title_full Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title_fullStr Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title_full_unstemmed Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title_short Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis
title_sort novel m. tuberculosis specific il-2 elispot assay discriminates adult patients with active or latent tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983515/
https://www.ncbi.nlm.nih.gov/pubmed/29856871
http://dx.doi.org/10.1371/journal.pone.0197825
work_keys_str_mv AT dellabellachiara novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT spiniccimichele novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT grassialessia novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT bartalesifilippo novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT benagianomarisa novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT truthmannkatja novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT tapinassisimona novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT troiloarianna novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT deliossofia novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT alnwaisriheba novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT shuraleveduard novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT singhmahavir novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT bartolonialessandro novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis
AT deliosmariomilco novelmtuberculosisspecificil2elispotassaydiscriminatesadultpatientswithactiveorlatenttuberculosis